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Abstract
Background: Both obstructive sleep apnea (OSA) and a novel lipocalin, neutrophil gelatinase associated lipocalin (Ngal),
have been reported to be closely linked with cardiovascular disease and loss of kidney function through chronic
inflammation. However, the relationship between OSA and Ngal has never been investigated.
Objectives: To evaluate the relationship between Ngal and OSA in clinical practice.
Methods: In 102 patients, polysomnography was performed to diagnose OSA and plasma Ngal levels were measured. The
correlations between Ngal levels and OSA severity and other clinical variables were evaluated. Of the 46 patients who began
treatment with continuous positive airway pressure (CPAP), Ngal levels were reevaluated after three months of treatment in
25 patients.
Results: The Ngal level correlated significantly with OSA severity as determined by the apnea hypopnea index (r = 0.24,
p = 0.01) and 4% oxygen desaturation index (ODI) (r = 0.26, p = 0.01). Multiple regression analysis showed that the Ngal level
was associated with 4%ODI independently of other clinical variables. Compliance was good in 13 of the 25 patients who
used CPAP. Although the OSA (4%ODI: 33.1616.7 to 1.161.9/h, p,0.01) had significantly improved in those with good
compliance, the Ngal levels were not significantly changed (60.5618.1 before CPAP vs 64.2613.9 ng/ml after CPAP,
p = 0.27).
Conclusions: Plasma Ngal levels were positively associated with the severity of OSA. However, the contribution rate of OSA
to systemic Ngal secretion was small and changes in Ngal levels appeared to be influenced largely by other confounding
factors. Therefore, it does not seem reasonable to use the Ngal level as a specific biomarker of OSA in clinical practice.
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Introduction
Neutrophil gelatinase associated lipocalin (Ngal), also known as
lipocalin 2, is a 25-kDa secretory glycoprotein that was originally
identified in human neutrophils. This protein was originally
known as an innate immunity antibacterial factor released by
activated neutrophils. [1,2] It has also become known to be
produced by renal tubular cells in response to different types of
injury. [3] Based on experimental and clinical findings, Ngal is
widely considered as an excellent indicator of acute and chronic
kidney injury.[3–7] Moreover, because this protein is also released
by endothelial cells and failing myocardium, a close relationship
between blood Ngal levels and heart failure or cardiovascular
diseases has been suggested.[8–10].
Obstructive sleep apnea (OSA) is a highly prevalent disorder,
affecting about 4–20% of adults and is characterized by repetitive
episodes of partial or complete obstruction of the upper airway
during sleep associated with transient oxygen desaturation.[11–13]
Accumulating clinical evidence suggests that OSA is an in-
dependent risk factor for cardiovascular disease and loss of kidney
function through nocturnal hypoxia and chronic inflamma-
tion.[14–17] From an in vitro model of OSA, it was suggested
that the pro-inflammatory transcription factor, nuclear factor-
kappa B (NF-kB), plays an important role in the inflammatory
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process of a cell’s reaction to intermittent hypoxia/reoxygenation.
[18] Meanwhile, it has been reported that several inflammatory
stimuli, such as interleukin 1b, stimulate systemic Ngal expression
and secretion. NF-kB also has been shown to transactivate Ngal
expression, suggesting that Ngal might be involved in inflamma-
tory responses. [19,20].
Therefore, a positive correlation between OSA severity and
systemic Ngal secretion through chronic inflammation seems
possible. However, this relationship has never been investigated.
Thus, we hypothesized that blood Ngal levels are elevated in
patients with OSA and that its levels are modified by the treatment
of OSA with continuous positive airway pressure (CPAP). In the
present study, we measured plasma Ngal levels in patients with
OSA and evaluated its utility in clinical practice.
Methods
Subjects
Study patients were consecutively recruited from the Sleep Unit
of Kyoto University Hospital between January 2009 and May
2012. All had been referred to our sleep unit under suspicion of
OSA with symptoms such as habitual snoring or daytime
sleepiness. None had been previously diagnosed with or treated
for OSA. Patients with overt renal failure (serum creatinine
.1.3 mg/dl) or with any history of cardiovascular diseases, heart
failure or arrhythmia were excluded because severe renal and/or
heart failure can directly affect plasma Ngal levels. Also excluded
were patients with pulmonary diseases, chronic infection, history
of cancer or collagen disease. Since a consensus about the
relationship between Ngal levels and metabolic syndrome has not
yet been formed, we aimed to evaluate the correlations between
risk factors for metabolic syndrome and plasma Ngal levels in
actual clinical practice. We did not exclude patients with
components of metabolic syndrome such as hypertension, diabetes
and dyslipidemia even if they were under treatment for these
comorbidities.[21–23] This study was approved by Kyoto
University Graduate School and Faculty of Medicine Ethics
Committee, and written informed consent was obtained from all
patients.
Polysomnography and CPAP Implementation
The diagnosis of OSA was confirmed by polysomnography
(SomnoStar pro, Cardinal Health, Dublin, OH, USA or Alice 4,
Philips Respironics, Inc., Murrysville, PA, USA), which was
started at 22:00 and ended at 6:00 the following morning. Surface
electrodes were attached using standard techniques to obtain an
electrooculogram, electromyogram of the chin and 12-lead
electroencephalograph. Sleep stages were defined according to
the criteria of Rechtchaffen and Kales. [24] Ventilation was
monitored by inductive plethysmography (Respitrace QDC,
Viasys Healthcare, Palm Springs, CA, USA). Airflow was
monitored by a nasal pressure transducer and supplemented by
an oronasal thermal sensor. Arterial oxygen saturation (SpO2) was
monitored continuously with a pulse oximeter.
Apnea was defined as the continuous cessation of airflow for
more than 10 seconds and hypopnea was defined as a reduction in
airflow of 30% or more lasting for 10 seconds or more
accompanied by a decrease in SpO2 of at least 4%. [25] Apnea-
hypopnea index (AHI) values were calculated as the number of
episodes of apnea and hypopnea per hour over the total sleep time.
4% oxygen desaturation index (ODI) values were defined as the
Table 1. Baseline characteristics and data on metabolic syndrome and its components in study patients.
non OSA (n=15) mild OSA (n=37) moderate OSA (n=24) severe OSA (n=26) p
Age (y) 48.2617.2 55.1613.3 57.3614.5 58.6611.5 0.12
Sex (male), n(%) 8 (53.3) 24 (64.9) 18 (75) 18 (69.2) 0.56
Smoking status never/ex/current, n 2/3/10 5/13/19 3/5/16 3/8/15 0.88
Body mass index (kg/m2) 23.563.7 25.164.6 24.864.1 29.267.8a,b,c ,0.01
Neck circumference (cm) 36.263.1 37.963.7 37.863.6 39.864.0a 0.03
Waist circumference (cm) 84.3611.5 90.1613.1 89.7611.0 98.6614.4a,b 0.01
Hip circumference (cm) 90.368.8 94.6610.6 92.169.3 101.3615.3a,c 0.01
Waist-to-hip ratio 0.9360.07 0.9560.05 0.9760.04 0.9760.03 0.04
SBP (mmHg) 119.8616.1 124.2616.3 127.3612.9 127.4616.0 0.40
DBP (mmHg) 72.7611.9 76.7611.5 78.6611.2 76.2612.0 0.50
Percentages of patients with metabolic syndrome or components of metabolic syndrome
Hypertension, n (%) 7 (46.7) 20 (54.1) 15 (62.5) 19 (73.1) 0.16
Hyperglycemia, n (%) 5 (33.3) 7 (18.9) 4 (16.7) 5 (19.2) 0.56
Dyslipidemia, n(%) 6 (40.0) 16 (43.2) 11 (45.8) 13 (50.0) 0.98
Visceral fat accumulation, n(%) 7 (46.7) 22 (59.5) 18 (75.0) 23 (88.5) 0.01
Metabolic syndrome, n(%) 5 (33.3) 13 (35.1) 8 (33.3) 11 (42.3) 0.90
Percentages of patients under treatment for components of metabolic syndrome
Hypertension, n (%) 2 (13.3) 14 (37.8) 9 (37.5) 12 (46.2) 0.16
Diabetes, n (%) 2 (13.3) 3 (8.1) 2 (8.3) 5 (19.2) 0.56
Dyslipidemia, n(%) 4 (26.7) 8 (21.6) 5 (20.8) 6 (23.1) 0.98
Data are expressed in mean 6 SD or n (%).
OSA: obstructive sleep apnea; SBP: systolic blood pressure; DBP: diastolic blood pressure;
ap,0.05 vs non OSA; bp,0.05 vs mild OSA; cp,0.05 vs moderate OSA.
doi:10.1371/journal.pone.0054184.t001
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number of desaturations $4% per hour of sleep. The length of
time SpO2,90% during sleep was calculated in each patient.
Patients with central sleep apnea were excluded. OSA severity was
defined by the AHI as follows: non OSA (AHI,5), mild OSA
(5#AHI,15), moderate OSA (15#AHI,30) and severe OSA
(30#AHI).
Patients with an AHI $15 were candidates for nasal CPAP.
Those who agreed with CPAP implementation underwent
a second polysomnography with CPAP titration. We implemented
CPAP with the auto adjusting positive airway pressure (PAP)
function for all patients. Based on the second sleep study,
minimum and maximum PAP were determined to abolish all
respiratory events, arousal and desaturation events.
Follow-Up
At the three-month follow-up, we urged the patients to undergo
a third sleep study to confirm whether an adjustment of the CPAP
setting was necessary. To investigate the effect of CPAP treatment
on plasma Ngal levels, at the third sleep study blood samples were
collected in the same way as at the first sleep study. We also
checked use time of the CPAP machine by reading the time
counter on the CPAP machines. Similar to prior studies, we
defined ‘good compliance’ as the use of CPAP for .4 h per night
on .70% of nights and categorized the patients into two groups,
those with ‘good compliance’ or ‘poor compliance’. [26] We
analyzed the data separately for each group and compared clinical
variables before and after CPAP treatment.
Blood Sampling and Measurement of Plasma Ngal Level
Blood samples were drawn at 7:00 in the morning after the
subjects had fasted beginning at 20:00 the previous night. Blood
samples were centrifuged immediately at 3,000 rpm at 4uC for
10 min. The separated samples were stored 280uC until assay.
Plasma Ngal concentrations were determined by an ELISA kit
provided by Bioporto Diagnostics, Gentofte, Denmark. Intra- and
inter-assay coefficients of variation for Ngal were 1.2–4.0% and
2.2–11.2%, respectively.
Definition of Metabolic Syndrome
In classifying patients based on the components of metabolic
syndrome, we utilized Japanese criteria. [27] Waist circumference
(WC) was measured at the level of the navel with the patient
standing, and visceral fat accumulation was determined to be
positive at WC $85 cm for men and $90 cm for women. A
diagnosis of metabolic syndrome required the subject to have
visceral fat accumulation and 2 or 3 of the following: (a)
dyslipidemia (triglycerides $150 mg/dL and/or high-density
lipoprotein cholesterol level ,40 mg/dL, or specific treatment
for these lipid abnormalities); (b) hypertension (systolic blood
pressure $130 mmHg and/or diastolic blood pressure
$85 mmHg, or treatment of previously diagnosed hypertension);
and (c) hyperglycemia (fasting plasma glucose $110 mg/dL or
specific treatment for diabetes mellitus). Anthropometric param-
eters and blood pressure were measured immediately after
polysomnography recording ended.
Statistical Analysis
In the analysis of data, we classified the patients depending on
the severity of OSA and compared their clinical backgrounds. We
also compared plasma Ngal levels between patients with and
without each component of metabolic syndrome to investigate the
relationships between plasma Ngal levels and metabolic syndrome.
Data were expressed as means 6 standard deviation. The
significance of intergroup differences based on the severity of
OSA was determined by an analysis of variance. When
a significant difference was found, we used the Tukey’s honestly
Table 2. OSA parameters and laboratory profiles.
non OSA (n=15) mild OSA (n=37)
moderate OSA
(n=24) severe OSA (n=26) p
Parameters of OSA
Apnea hypopnea index/h 2.261.6 9.462.6 22.265.0a,b 50.5619.8a,b,c ,0.01
4%ODI/h 1.861.6 8.263.3 20.766.0a,b 49.6620.2a,b,c ,0.01
Minimum SpO2 (%) 90.364.5 84.964.3 78.468.6
a,b 71.3612.2a,b,c ,0.01
Arousal index/h 24.3612.1 22.869.6 30.7613.2 43.4618.3a,b,c ,0.01
Length of time SpO2,90% (m) 3.265.4 11.4617.4 37.3652.2 121.16107.8
a,b,c ,0.01
Laboratory profiles
FPG (mg/dl) 107.7639.9 95.4620.1 96.4624.3 102.5620.2 0.35
HbA1c (%) 5.8061.22 5.4960.65 5.4560.91 5.7460.86 0.45
Total cholesterol (mg/dl) 185.5632.3 195.2635.4 203.0644.0 201.5644.0 0.53
LDL cholesterol (mg/dl) 103.2627.9 116.2627.8 118.5636.8 109.5631.8 0.40
HDL cholesterol (mg/dl) 55.2612.9 52.8613.5 53.0616.1 51.9613.9 0.91
Triglycerides (mg/dl) 125.1686.5 119.8658.0 139.1679.1 168.06185.2 0.39
BNP (pg/ml) 14.468.7 20.6624.4 22.4631.8 21.5618.7 0.73
Creatinine (mg/dl) 0.7260.19 0.7460.15 0.8060.17 0.7860.21 0.45
Ngal (ng/ml) 46.966.0 48.9610.9 51.3615.2 55.4616.7 0.16
Data are expressed in mean 6 SD or n (%).
OSA: obstructive sleep apnea; ODI: oxygen desaturation index; SpO2: saturation of oxygen; FPG: fasting plasma glucose; LDL: low density lipoprotein; HDL: high density
lipoprotein; BNP: brain natriuretic peptide; Ngal: neutrophil gelatinase associated lipocalin.
ap,0.05 vs non OSA; bp,0.05 vs mild OSA; cp,0.05 vs moderate OSA.
doi:10.1371/journal.pone.0054184.t002
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significant difference procedure to identify where the difference
was significant. A chi-square test and the Mann-Whitney U test
were used to compare categorical and continuous variables,
respectively. We used Pearson’s coefficient tests to evaluate the
relationship between the plasma Ngal level and other continuous
variables. Based on the results of this analysis, multiple regression
analyses were performed to clarify the contribution rate of OSA
and other comorbidities to systemic Ngal secretion. Wilcoxon
signed rank test was used to compare clinical variables before and
after CPAP treatment. Two-tailed p-values,0.05 were considered
statistically significant. All statistical analyses were performed using
JMP 7.0.2 statistical software (SAS Institute Inc., Cary, NC, USA).
Results
Baseline Characteristics of Study Patients
A total of 102 patients were studied, and their baseline
characteristics are shown in table 1.Those with severe OSA were
characterized by a significantly higher body mass index (BMI)
than in the other three groups. The percentages of patients who
fulfilled the criterion for visceral fat accumulation increased as the
severity of OSA increased. Other anthropometric parameters with
significant differences among the groups are also shown in table 1.
With the exception of the parameters for OSA, there were no
significant differences among the four groups in other clinical
background factors. (Tables 1 and 2).
Plasma Ngal Levels in Patients at Diagnosis and follow up
Table 2 shows baseline plasma Ngal levels in the four groups,
with no statistically significant differences found among them.
However, simple linear regression analysis showed significant
correlations of the plasma Ngal level with the following parameters
of OSA: AHI (r = 0.24, p = 0.01), 4%ODI (r = 0.26, p = 0.01) and
time of SpO2,90% (r = 0.23, p = 0.02). (Figure 1) The plasma
Ngal level was also correlated with values for serum low density
lipoprotein (LDL) cholesterol (r =20.31, p,0.01), triglycerides
(r = 0.24, p= 0.01) and creatinine (r = 0.34, p,0.01). On the other
hand, none of anthropometric parameters and parameters
associated with diabetes such as fasting plasma glucose and
HbA1c levels showed significant correlations with Ngal
levels.(Table 3) Furthermore, in the present cohort, significant
differences were not found in plasma Ngal levels between patients
with and without each of the components of metabolic syndrome.
(Table 4).
For the multiple regression analysis, we chose 4%ODI as the
representative variable for OSA severity as it had the best
correlation with the Ngal level among OSA parameters in the
simple correlation analysis. The analysis demonstrated that
4%ODI was associated with the Ngal level independently of
creatinine and LDL-cholesterol levels. The contribution rate of
4% ODI to the Ngal level was 6.2% (Table 5).
Figure 1. Simple correlations between plasma neutrophil gelatinase associated lipocalin (Ngal) levels and parameters of
obstructive sleep apnea. AHI: apnea hypopnea index; ODI: oxygen desaturation index; SpO2: saturation of oxygen.
doi:10.1371/journal.pone.0054184.g001
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CPAP was implemented for 46 of the 50 patients with moderate
or severe OSA. Of the 46 patients, 27 agreed to a follow-up sleep
study. Just before the reevaluation, cardiac medicine was pre-
scribed for one patient and an upper airway infection was found in
another patient. These two patients were excluded from the
analysis, and the remaining 25 patients were reevaluated. Thirteen
were categorized into the good compliance group and the other 12
patients into the poor compliance group. Those in the good
compliance group were significantly older than patients in the
poor compliance group. The determined maximum and minimum
PAP did not differ between the two groups.
After CPAP implementation, OSA was significantly improved
in both groups. In the good compliance group, despite improve-
ments in OSA, no significant change was noted in plasma Ngal
levels from values before CPAP use. Furthermore, in the poor
compliance group, Ngal levels were significantly elevated after
CPAP implementation. There were not significant differences in
the other confounding factors before and after CPAP treatment
(Table 6).
Discussion
In this cross sectional evaluation, although significant differ-
ences in plasma Ngal levels were not found among groups
classified according to the severity of OSA, parameters of OSA,
such as 4%ODI and AHI per se, correlated with plasma Ngal
levels in regression analysis. This suggests that OSA contributes,
although weakly, to elevated plasma Ngal levels through nocturnal
hypoxia. Because it has been reported that hypoxia induces an
elevation in plasma Ngal levels in an experimental animal model,
it is possible that OSA induces Ngal elevation through nocturnal
intermittent hypoxia. [28] To the best of our knowledge, this is the
first report to evaluate the relationship between the Ngal protein
level and OSA severity in clinical practice.
The relationship between another protein in the lipocalin family
and OSA has been investigated. Makino et al and Nena et al,
respectively, investigated the relationship between the plasma level
of retinol binding protein 4 (RBP-4), which also belongs to the
lipocalin protein family, and OSA. [29,30] However, neither study
found a correlation between RBP-4 levels and apnea-related
indices. Although both Ngal and RBP-4 belong to the lipocalin
family and share a common tertiary structure, these two proteins
appear to have different patterns of regulation in response to
inflammatory mediators. [21,23].
Our results also demonstrated a significant inverse correlation
between Ngal and LDL cholesterol levels. Wallenius et al also
reported such an inverse correlation in their epidemiological study.
[21] However, in other studies, correlations between these two
variables were not found. [23,31,32] Although this inverse
correlation is possible, the results seem to vary depending on the
clinical characteristics of the examined cohorts. Furthermore, the
mechanisms of this correlation remain utterly unknown.
The relationship between Ngal and metabolic syndrome is quite
controversial. Whereas Wang et al and Yan et al reported a close
Table 3. Simple correlations between plasma neutrophil
gelatinase associated (Ngal) levels and clinical variables.
r p
Age (y) 0.04 0.62
Body mass index (kg/m2) 0.13 0.17
Neck circumference (cm) 0.00 0.84
Waist circumference (cm) 0.00 0.91
Hip circumference (cm) 0.00 0.99
Waist-to-hip ratio 0.03 0.76
SBP (mmHg) 0.00 0.96
DBP (mmHg) 20.13 0.17
FPG(mg/dl) 20.08 0.39
HbA1c (%) 20.06 0.52
Total cholesterol (mg/dl) 0.12 0.21
LDL-cholesterol (mg/dl) 20.31 ,0.01
HDL-cholesterol (mg/dl) 20.18 0.06
Triglycerides (mg/dl) 0.24 0.01
BNP (pg/ml) 0.00 0.74
Creatinine (mg/dl) 0.34 ,0.01
r: correlation coefficient; SBP: systolic blood pressure; DBP: diastolic blood
pressure; FPG: fasting plasma glucose; LDL: low density lipoprotein; HDL: high
density lipoprotein; BNP: brain natriuretic peptide.
doi:10.1371/journal.pone.0054184.t003
Table 4. Plasma Ngal levels in patients with and without each
component of metabolic syndrome.
Plasma Ngal levels (ng/ml)
Comorbidity(+) Comorbidity(2) p
Hypertension 52.761.7 48.062.1 0.17
(n = 61) (n = 41)
Hyperglycemia 48.4614.5 51.4613.0 0.27
(n = 21) (n = 81)
Dyslipidemia 51.9614.7 49.9612.2 0.49




(n = 70) (n = 32)
Metabolic syndrome 51.8616.7 50.2611.1 0.93
(n = 37) (n = 65)
Data are expressed in mean 6 SD.
Ngal: neutrophil gelatinase associated lipocalin.
doi:10.1371/journal.pone.0054184.t004
Table 5. Multiple regression analyses using plasma
neutrophil gelatinase associated lipocalin (Ngal) level as
a dependent variable.
p b r R2(%)
Body mass index (kg/m2) 0.39 –
4%ODI/h ,0.01 0.24 0.26 6.2
LDL-cholesterol (mg/dl) ,0.01 20.29 20.31 9.0
HDL-cholesterol (mg/dl) 0.71 –
Triglycerides (mg/dl) 0.31 –
Creatinine (mg/dl) ,0.01 0.28 0.34 9.5
Cumulative R2 24.7
b: standard regression coefficient; r: correlation efficient; R2: contribution rate;
ODI: oxygen desaturation index; LDL: low density lipoprotein; HDL: high density
lipoprotein.
doi:10.1371/journal.pone.0054184.t005
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association between Ngal and obesity or insulin resistance,
Wallenius et al found no correlation between these risk factors.
[21,22,31] Our results did not show any significant correlation
between Ngal levels and obesity or diabetic indices. Also, in the
present cohort there were no significant differences in Ngal levels
between patients with and without metabolic syndrome. These
results also seem to depend on the clinical characteristics of the
cohorts. Specifically, we did not exclude patients under treatment
for metabolic syndrome to investigate the utility of the plasma
Ngal level in actual clinical practice. Because it was reported that
the pharmaceutical treatment of diabetes and dyslipidemia can
change plasma Ngal levels, treatment of metabolic syndrome in
our cohort possibly affected the results. [31,33] Furthermore, in
most of these studies, renal function was not taken into account as
an explanatory variable of the Ngal level. Risk factors for
metabolic syndrome induce latent renal function impairment
and even a subtle change in renal function is known to affect blood
and urinary Ngal levels. [34] Giaginis et al reported that plasma
Ngal levels were higher in patients with than without hypertension
and they speculated that the association between elevated Ngal
levels and hypertension is secondary to the confounding effect of
renal impairment. [35] In our study, even though we did not
include patients with overt renal failure, the plasma Ngal levels
correlated significantly with serum creatinine levels. Therefore, in
evaluating the direct link between metabolic syndrome and Ngal
levels, statistical correction for renal function seem to be necessary.
In fact, Liu et al reported that the significant correlation between
Ngal and insulin resistance detected in their study cohort
disappeared after adjustment for serum creatinine values. [32].
Contrary to our expectation, plasma Ngal levels did not change
even with the appropriate use of CPAP that effected an
improvement in OSA. We could not confirm a direct causality
between Ngal levels and OSA. Although we based the three-
month treatment observation period on experiences in previous
studies, we might need an extended period to find more
remarkable changes in Ngal levels in the present cohort. [23,31].
Ngal levels were elevated after CPAP implementation in
patients with poor compliance with CPAP. Because we did not
include an actual control group that did not use CPAP, we could
not judge whether the change in Ngal levels was caused by
incomplete CPAP use or other reasons. Although we took every
conceivable confounding factor into account, other determinants
that we were not aware of might have influenced the results. In the
cross sectional studies, the contribution rate of 4%ODI to Ngal
levels was not large (6.2%). Therefore, it seems quite possible that
other determinants negated the influence of the improvement in
OSA. The presence of certain components of metabolic syndrome
and their treatment in the present cohort might be among these
determinants.
We recognize several limitations in the present study. First, the
sample size was small, so it is not reasonable to extrapolate our
data to the general population. In addition, the results of this study
might have been influenced by the small sample size. Second, as
we previously noted, we did not exclude patients with comorbid-
ities such as hypertension and diabetes even if they were under
treatment. It is possible that these comorbidities and their
treatment affected the results. Third, as mentioned above, we
did not have a planned control group without CPAP use.
Therefore, we could not judge precisely whether changes in Ngal
levels after CPAP implementation were caused by CPAP use or
other reasons. Lastly, we did not measure C reactive protein (CRP)
levels. Because inflammation has an influence on Ngal, results of
measurement of high sensitive CRP would have been a good
reflection of the inflammation status of patients and would have
been helpful to achieve a more comprehensive understanding of
the relationship between OSA and Ngal.
In summary, the present study provides the first clinical
evidence demonstrating that plasma Ngal levels were positively
but weakly associated with the severity of OSA. Plasma Ngal levels
did not change after improvement in OSA, so we could not testify
to the causality between Ngal levels and OSA severity. Because
Ngal levels were just weakly correlated with the severity of OSA,
changes in those levels appear to be influenced largely by other
confounding factors. Thus, it would be difficult to use the Ngal
level as a specific biomarker representing nocturnal hypoxia in
OSA. The links between Ngal levels and metabolic syndrome
remain controversial, and unrecognized determinants of plasma
Ngal levels are likely to be present. Further studies are warranted
to more comprehensively understand the regulation of Ngal in
relation to OSA and metabolic syndrome.
Table 6. Changes in clinical variables from baseline to after CPAP implementation.
CPAP good compliance (n =13) CPAP poor compliance (n =12)
before CPAP after CPAP p* before CPAP after CPAP p* p#
Ngal (ng/ml) 60.5618.1 64.2613.9 0.27 52.8616.8 63.1614.2 ,0.01 –
4%ODI (/h) 33.1616.7 1.161.9 ,0.01 41.5622.5 1.562.3 ,0.01 –
Creatinine (mg/dl) 0.8560.20 0.8860.19 0.13 0.7760.21 0.7960.20 0.25 –
LDL cholesterol (mg/dL) 107.5632.7 103.8630.8 0.70 115.2628.2 121.0628.0 0.58 –
Body mass index (kg/m2) 23.962.0 23.962.2 0.85 28.266.6 28.666.6 0.14
Age (y) 67.568.3 – 54.5612.2 – 0.01
Days with CPAP use .4 h (%) 85.869.6 – 43.3620.7 – ,0.01
Maximum PAP (cmH2O) 9.962.8 – 10.862.5 – 0.62
Minimum PAP (cmH2O) 4.560.9 – 4.760.8 – 0.35
Data are expressed in mean6SD.
CPAP: continuous positive airway pressure; Ngal: neutrophil gelatinase associated lipocalin; ODI: oxygen desaturation index; LDL: low density lipoprotein; PAP: positive
airway pressure; p*: p value for comparison with values before and after CPAP treatment; p# : p value for comparison between CPAP good compliance and CPAP poor
compliance groups.
doi:10.1371/journal.pone.0054184.t006
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